POINT BIOPHARMA GLOBAL INC.: 10-Q filed 2023-11-13

Name: POINT BIOPHARMA GLOBAL INC.: 10-Q filed 2023-11-13
Creator: POINT BIOPHARMA GLOBAL INC.

What POINT BIOPHARMA GLOBAL INC. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 41 published measures, 120 facts as tagged in accession 0001811764-23-000046.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-13
Fiscal period: fiscal Q3 2023
Accession: 0001811764-23-000046 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All POINT BIOPHARMA GLOBAL INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	477,704,420	USD
At 2022-12-31	578,322,736	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	53,512,034	USD
At 2022-12-31	91,368,943	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	21,607,412	USD
At 2022-12-31	286,428,371	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-24,774,353	USD	92
2023-01-01 to 2023-09-30	-66,715,863	USD	273
2023-04-01 to 2023-06-30	-25,410,839	USD	91
2023-01-01 to 2023-03-31	-16,530,671	USD	90
2022-07-01 to 2022-09-30	-24,013,069	USD	92
2022-01-01 to 2022-09-30	-64,973,890	USD	273
2022-04-01 to 2022-06-30	-24,580,247	USD	91
2022-01-01 to 2022-03-31	-16,380,574	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-124,859,499	USD	273
2022-01-01 to 2022-09-30	-53,397,277	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	17,249,510	USD	273
2022-01-01 to 2022-09-30	10,696,365	USD	273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,789,993	USD	92
2023-01-01 to 2023-09-30	17,113,113	USD	273
2022-07-01 to 2022-09-30	0	USD	92
2022-01-01 to 2022-09-30	0	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	45,973	USD	273
2022-01-01 to 2022-09-30	116,902,265	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-140,007,433	USD	273
2022-01-01 to 2022-09-30	-176,537,853	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-27,707,358	USD
At 2022-12-31	39,008,505	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	105,765,954	shares	92
2023-01-01 to 2023-09-30	105,717,330	shares	273
2022-07-01 to 2022-09-30	92,401,484	shares	92
2022-01-01 to 2022-09-30	90,891,031	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	105,765,954	shares	92
2023-01-01 to 2023-09-30	105,717,330	shares	273
2022-07-01 to 2022-09-30	92,401,484	shares	92
2022-01-01 to 2022-09-30	90,891,031	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.23	USD/shares	92
2023-01-01 to 2023-09-30	-0.63	USD/shares	273
2022-07-01 to 2022-09-30	-0.26	USD/shares	92
2022-01-01 to 2022-09-30	-0.71	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.23	USD/shares	92
2023-01-01 to 2023-09-30	-0.63	USD/shares	273
2022-07-01 to 2022-09-30	-0.26	USD/shares	92
2022-01-01 to 2022-09-30	-0.71	USD/shares	273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	871,449	USD	92
2023-01-01 to 2023-09-30	-288,491	USD	273
2022-07-01 to 2022-09-30	180,500	USD	92
2022-01-01 to 2022-09-30	452,021	USD	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	4,596,277	USD	273
2022-01-01 to 2022-09-30	2,547,069	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-29,626,162	USD	92
2023-01-01 to 2023-09-30	-83,588,619	USD	273
2022-07-01 to 2022-09-30	-24,637,032	USD	92
2022-01-01 to 2022-09-30	-65,840,105	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	353,246,546	USD
At 2022-12-31	530,822,730	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	38,666,277	USD
At 2022-12-31	79,738,440	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	8,886,750	USD
At 2022-12-31	7,703,150	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	32,416,155	USD	92
2023-01-01 to 2023-09-30	100,701,732	USD	273
2022-07-01 to 2022-09-30	24,637,032	USD	92
2022-01-01 to 2022-09-30	65,840,105	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	26,910,286	USD	92
2023-01-01 to 2023-09-30	85,097,331	USD	273
2022-07-01 to 2022-09-30	20,797,406	USD	92
2022-01-01 to 2022-09-30	54,112,136	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	105,765,954	shares
At 2022-12-31	105,649,741	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	21,607,412	USD
At 2022-12-31	286,428,371	USD
At 2022-09-30	125,783,126	USD
At 2021-12-31	238,815,991	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	453,319,762	USD
At 2022-12-31	448,391,574	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-09-30	-1,430,594	USD
At 2022-12-31	-456,851	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2023-09-30	424,192,386	USD
At 2023-06-30	447,451,918	USD
At 2023-03-31	471,779,776	USD
At 2022-12-31	486,953,793	USD
At 2022-09-30	309,079,832	USD
At 2022-06-30	215,382,303	USD
At 2022-03-31	239,273,904	USD
At 2021-12-31	255,213,086	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-09-30	5,505,693	USD
At 2022-12-31	0	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	5,582,548	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	14,529,354	USD
At 2022-12-31	19,094,454	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	9,901,729	USD
At 2022-12-31	5,610,889	USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

Period	Value	Unit	Days
At 2023-09-30	12,586,443	USD
At 2022-12-31	23,242,290	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-23,902,904	USD	92
2023-01-01 to 2023-09-30	-67,004,354	USD	273
2022-07-01 to 2022-09-30	-23,832,569	USD	92
2022-01-01 to 2022-09-30	-64,521,869	USD	273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-66,715,863	USD	273
2022-01-01 to 2022-09-30	-64,973,890	USD	273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-25,135,964	USD	92
2023-01-01 to 2023-09-30	-67,689,606	USD	273
2022-07-01 to 2022-09-30	-24,279,389	USD	92
2022-01-01 to 2022-09-30	-65,582,588	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	5,505,869	USD	92
2023-01-01 to 2023-09-30	15,604,401	USD	273
2022-07-01 to 2022-09-30	3,839,626	USD	92
2022-01-01 to 2022-09-30	11,727,969	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,186,253	USD	273
2022-01-01 to 2022-09-30	980,995	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	5,723,258	USD	92
2023-01-01 to 2023-09-30	16,584,265	USD	273
2022-07-01 to 2022-09-30	804,463	USD	92
2022-01-01 to 2022-09-30	1,318,236	USD	273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	31,924,135	USD	273
2022-01-01 to 2022-09-30	411,424	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	116,856,162	USD	273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	167,397	USD	273

Inspect the source

Entity: POINT BIOPHARMA GLOBAL INC. / CIK 0001811764
Captured: 2026-09-22 19:56 UTC
SEC response SHA-256: 3030a0d9bffc12ba00b52fe176e9bfd2cab34f010d097842851d71ae05b2a775

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001811764.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))